← Every issue

MedTech Leading Voice · Issue 189 · 8 Nov 2026

MDR and IVDR Evidence Requirements in Transition

Deadlines ran through this week’s posts. Beat Keller reminded MDD certificate holders that the deadlines to stay in the MDR transition passed in 2024.

By Sean Smith Read on LinkedIn ↗
Issue 189 cover

MDR and IVDR Evidence Requirements in Transition

MedTech Leading Voice | Issue 189

📝 From the Editor

Deadlines ran through this week’s posts. Beat Keller reminded MDD certificate holders that the deadlines to stay in the MDR transition passed in 2024. Stefano Bolletta flagged 27 March 2027 as the latest recommended date for manufacturers to upload their own SS(C)Ps to EUDAMED. MDCG 2026-6 on orphan IVDs and ISO 20417:2026 were also published.

Last Friday, Maria E. Donawa, M.D. , walked 158 of us through how clinical data is appraised under the MDR. This Friday, Ethan Drower of CiteMed shows how to build the system that supports your claims.

— Sean Smith

🧠 Featured Post

Your MDD Certificate Runs to 2028. Did You Meet the 2024 Deadlines That Keep It Valid?

Beat Keller starts from a familiar assumption: the MDD certificate is valid until 2028, so there is still time. The extended transition periods under Article 120 MDR, as amended by Regulation (EU) 2023/607, are conditional. Each condition had a 2024 deadline. Companies needed a formal application to a notified body by 26 May 2024, a written agreement signed by 26 September 2024, and a QMS upgraded for MDR risk management and post-market surveillance by 26 May 2024.

The 31 December 2027 deadline (Class III and implantable Class IIb) and the 31 December 2028 deadline (other Class IIb, Class IIa, Class Is/Im/Ir) apply only when all three conditions were met. The device must also still comply with the MDD, have no significant change in design or intended purpose, and present no unacceptable risk. If a legacy device misses any of these, Beat’s line is that “the dates on your certificate are decoration.”

View the post >>

📌 This Week’s Top Posts (In no special order)

🎯 Featured Event

Architecting a Claims Support System

Friday, November 13, 2026, 11:00 AM ET — How evidence leaders answer the EU, the FDA and their payers without starting over. This Friday In-Focus features Ethan Drower, Co-Founder and CEO of CiteMed.

Last week, Maria E. Donawa, M.D., showed that claims on your label, IFU, website or sales materials may have to come down if your clinical data doesn’t support them. Ethan’s session covers how to build the system that supports those claims.

Register Now >>

🗓️ Upcoming Events & Webinars

🎟️ Upcoming Conferences

  • November 10–11 | Philadelphia, PA — PhMTI 2026 Fall Seminar: Human + Machine, The Enduring Value of Information Professionals in the Age of AI, at the Sofitel Philadelphia at Rittenhouse Square. Member rate $200. Register Now >>

💥 Weekly 510(k) Roundup

November 2, 2026 | From Marcus Engineering, LLC

71 clearances this week, including 28 first-time clearances (🚀). Featured clearances:

  • 🚀 Evident Vascular, Inc. — Evident Vascular™ Guidance System: a tiny probe sends out high-frequency sound waves and uses the echoes to image the inside of blood vessels. It shows plaque buildup and narrowing along vessel walls, which helps doctors choose and place the right stent and confirm blood flow.
  • 🚀 Bloom Surgical — SWICS™: a miniature wiper and fluid rinse clean the surgical camera lens while the camera stays inside the patient, so surgeons keep a clear view without pulling it out for cleaning.
  • LymphaTech — LymphaTech Mobile 3D Measuring Tool: an infrared camera and an iPad build an accurate 3D model of a patient’s arm or leg without touching it. This makes it easier to track swelling from lymphedema after cancer treatment.

Explore the update >>

📋 Regulatory Roundup

Monday, 2 November 2026 | By Martin King

This edition argues that regulatory intelligence has to turn into regulatory action. NMPA, SAHPRA, Swissmedic and ANVISA show compliance moving from guidance to implementation. Swissmedic, the Egyptian Drug Authority, FDA, EMA and Health Canada are making submission quality and structured regulatory data strategic priorities. EMA, ENISA, the European Data Protection Board and Hong Kong’s Department of Health are looking harder at digital systems, cybersecurity and data protection.

PIC/S, Swissmedic and FDA treat lifecycle quality management as a continuing responsibility. FDA and EMA are tying clinical evidence more closely to scientific innovation. MHRA, MedTech Europe and EMA show market access and regulatory cooperation becoming more connected. EMA, Health Canada, ANVISA, PIC/S and Swissmedic are advancing international harmonisation, though local requirements remain. Across global authorities, oversight has to connect the entire product lifecycle. This week’s edition is also available as a flipbook.

Explore the update >>

🎤 In Case You Missed It

Methodological Quality and Scientific Validity Under the MDR

Last Friday, more than 296 people registered, and 158 joined live from 34 countries for an outstanding session with Maria E. Donawa, M.D., Founder and President of Donawa Lifescience. Her subject was how clinical study data is appraised under the MDR. Following MEDDEV 2.7/1 rev 4, each data set is judged first on methodological quality and scientific validity, then on relevance, and then weighted for its contribution to the clinical evaluation.

In the live poll, 19 of 26 respondents said they were somewhat familiar with clinical data appraisal or new to it. Maria advised teams to bring clinical evaluation expertise into design and development, and to learn the appraisal criteria before writing the clinical investigation plan.

Watch the replay >>

🔥 Postscript

Don’t Be Overlooked

When a buyer asks AI for three names in your specialty, are you one of them? Get a free AI visibility audit, reviewed by me and in your inbox in 24 to 48 hours.

Message me to get your audit >>

Sean 🐝

Read this issue on LinkedIn ↗

Want this every Sunday? One email. Every expert named. Unsubscribe in one click.
Subscribe

Recent sessions

All sessions →
29 Oct 2026Want More Referrals? An MLVx Business Development Working Session 23 Oct 2026Want More Referrals: Turning Trust into Referrals 22 Oct 2026Clinical Project Management: The Hidden Complexity of Medical Device and IVD Studies